Tesamorelin (Egrifta, Theratechnologies) has a mean plasma elimination half-life of approximately 26 minutes per FDA NDA 022505.[1] This FDA-approved GHRH analog is dosed once daily at 2mg SC despite its short plasma half-life, because each injection triggers a GH pulse sufficient to reduce visceral adipose tissue over 24 hours via sustained IGF-1 elevation. Also known as: TH9507, Egrifta (brand), Egrifta SV.
The mean plasma elimination half-life of tesamorelin is approximately 26 minutes, with an observed range of 20–30 minutes across subjects in the pharmacokinetic studies supporting FDA NDA 022505.[1] This places tesamorelin well above native GHRH (~7 minutes) but far shorter than synthetic GHRH analogs with albumin-binding modifications such as CJC-1295 with DAC (~6–8 days).
The 26-minute figure derives from human pharmacokinetic studies conducted as part of the NDA 022505 submission for Egrifta (tesamorelin 2mg). These were controlled clinical PK studies in HIV-infected adults. Serial plasma samples were drawn following subcutaneous injection, and tesamorelin concentrations were measured by validated immunoassay. The data were analyzed using non-compartmental pharmacokinetic methods. This is high-confidence, regulatory-grade human PK data — not an in vitro estimate or animal extrapolation.
Tesamorelin's 26-minute plasma half-life describes the rate at which the peptide is cleared from circulation. It does not describe how long the biological effects last. Following a 2mg SC injection, tesamorelin stimulates a GH pulse from pituitary somatotrophs. This GH pulse drives hepatic IGF-1 synthesis over 12–24 hours — and it is IGF-1 elevation, along with direct GH-mediated lipolysis, that mediates tesamorelin's visceral fat-reducing effect.[2] Thus, a 26-minute plasma half-life is entirely compatible with once-daily dosing producing clinically meaningful 24-hour effects.
Using the standard pharmacokinetic rule of 5 half-lives for ~97% plasma clearance: 5 × 26 minutes = 130 minutes, or approximately 2.2 hours. Tesamorelin is essentially absent from plasma within 2–3 hours of a subcutaneous injection. The table below shows plasma clearance at each half-life interval.
| Time Post-Injection | Half-Lives Elapsed | % Remaining (Plasma) | Note |
|---|---|---|---|
| ~12–15 min (Tmax) | 0 (peak) | 100% | GH pulse begins |
| ~38–41 min | 1 | 50% | GH pulse ongoing |
| ~64–67 min | 2 | 25% | IGF-1 rising |
| ~90–93 min | 3 | 12.5% | Plasma nearly cleared |
| ~116–119 min | 4 | 6.25% | Essentially undetectable |
| ~130 min (~2.2 hr) | 5 | <3% | 97% plasma clearance |
Importantly, the IGF-1 elevation and lipolytic signaling triggered by each injection persist well beyond plasma clearance — typically 12–24 hours — explaining the clinical efficacy of once-daily dosing in the pivotal Falutz et al. phase 3 trials.[2]
The short plasma half-life of tesamorelin might seem incompatible with once-daily dosing, but the pharmacokinetic-pharmacodynamic (PK/PD) relationship explains the apparent paradox. When tesamorelin binds GHRH receptors on pituitary somatotrophs, it initiates a GH secretory response that far outlasts the drug's plasma presence. The GH pulse releases over 1–3 hours; the resulting hepatic IGF-1 synthesis peaks 6–20 hours later and remains elevated for approximately 24 hours.
In the pivotal phase 3 RCT (Falutz et al., NEJM 2007, n=412 HIV-infected adults), once-daily 2mg SC tesamorelin over 26 weeks reduced visceral adipose tissue (VAT) by a mean of 18% compared to placebo (p<0.0001), with sustained IGF-1 elevation throughout the treatment period.[2] No dose accumulation occurs; each day produces a fresh GH pulse of similar magnitude — approximating physiological pulsatile GH secretion.
Because tesamorelin has no plasma accumulation, a missed dose simply means the loss of one GH pulse on that day. Steady-state plasma concentrations do not exist in the traditional sense — each injection is an independent event. If a dose is missed, it should be skipped and normal dosing resumed the next day; doubling up doses is not recommended and not supported by the FDA label. The clinical effect of a single missed dose is minimal given that VAT reduction is driven by cumulative weeks of once-daily GH stimulation.
| Compound | Half-Life | Mechanism of Extension | Typical Dosing | Evidence Level |
|---|---|---|---|---|
| Tesamorelin | ~26 min | DPP-IV resistance (trans-3-hexenoic acid) | 2mg SC once daily | FDA-approved (NDA 022505) |
| Sermorelin | ~10–20 min | None (GHRH 1-29 truncated) | 0.2–0.3mg SC nightly | Clinical use; no FDA indication currently |
| CJC-1295 No DAC | ~30–60 min | Partial DPP-IV resistance | 100–200mcg SC 2–3×/day | Research use; no FDA approval |
| CJC-1295 with DAC | ~6–8 days | Drug Affinity Complex (albumin binding) | 1–2mg SC once weekly | Research use; no FDA approval |
The subcutaneous route is the only FDA-approved and clinically validated route for tesamorelin. The standard injection site is the abdomen, rotated daily. Following SC injection, absorption is slow relative to IV, with Tmax approximately 9–15 minutes (mean ~12 min). SC bioavailability is approximately 4% per the FDA label — relatively low due to pre-systemic proteolytic degradation at the injection site and in the subcutaneous interstitium.[1] Despite low SC bioavailability, the absolute amount of intact tesamorelin reaching the pituitary gland is sufficient to produce a robust GH pulse at the 2mg dose.
IV administration provides 100% bioavailability by definition and was used in PK reference studies to characterize tesamorelin's systemic distribution and clearance. The ~26-minute half-life was characterized using IV reference data alongside SC studies. IV administration is not used clinically.
There are no published pharmacokinetic data for intranasal tesamorelin. Given the peptide's molecular weight (~5135 Da) and susceptibility to mucosal proteases, intranasal bioavailability would be expected to be negligible without specialized delivery systems. Intranasal administration is not supported by the FDA label or clinical evidence.
Tesamorelin is an FDA-approved prescription medication (NDA 022505) and is not screened for on standard workplace or sports drug panels. As a peptide with a 26-minute plasma half-life, specialized liquid chromatography-tandem mass spectrometry (LC-MS/MS) could theoretically detect intact tesamorelin or its primary degradation fragments for approximately 1–3 hours after a subcutaneous injection. After approximately 2.2 hours (5 half-lives), plasma concentrations fall below the detection limit of most immunoassay methods. For anti-doping purposes, the World Anti-Doping Agency (WADA) classifies GHRH analogs as prohibited substances in sport regardless of prescription status; however, tesamorelin use in competitive athletes would require a therapeutic use exemption (TUE).
Native human GHRH(1-44) has a plasma half-life of approximately 6–7 minutes. This brevity is primarily due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV), a ubiquitous serine protease. DPP-IV cleaves the N-terminal Tyr-Ala bond at positions 1-2 of native GHRH, producing an inactive fragment.[4]
Tesamorelin carries a trans-3-hexenoic acid group at its N-terminus. This modification sterically blocks the DPP-IV active site, preventing cleavage of the adjacent Tyr-Ala bond. The result is a ~3.7-fold extension of plasma half-life: from ~7 minutes (native GHRH) to ~26 minutes (tesamorelin). Once DPP-IV cleavage is blocked, the remaining route of degradation is non-specific proteolysis by circulating peptidases, which proceeds at a slower rate.
Tesamorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs with high affinity. GHRHR is a G-protein coupled receptor; activation stimulates adenylate cyclase, increasing intracellular cAMP, which triggers GH synthesis and secretion. Each tesamorelin injection produces a GH pulse with amplitude proportional to dose. Unlike GHRP compounds (ipamorelin, GHRP-6), tesamorelin does not interact with ghrelin receptors and does not cause cortisol, ACTH, or prolactin elevation — a clinically important selectivity advantage.
The biological rationale for the trans-3-hexenoic acid modification is straightforward: native GHRH cannot be used as a therapeutic because its 7-minute half-life requires continuous IV infusion for sustained GH stimulation. Tesamorelin's 26-minute half-life is sufficient for SC injection to produce a full GH pulse after once-daily dosing, providing a practical therapeutic window. Sermorelin (GHRH 1-29) achieves similar practical dosing (nightly SC) with a somewhat shorter half-life (~10–20 min), whereas CJC-1295 with DAC dramatically extends this to ~6–8 days via albumin binding — a different mechanistic strategy entirely.
Halflife models your concentration curve, GH pulse timing, and IGF-1 elevation window — all on-device, free iOS app.
Download on App StoreSee your GH pulse timing, IGF-1 elevation window, and full PK curve — free iOS app, on-device, no account required.
Download on App Store